July 07, 2023
On July 1, 2023, Sandoz’s Hyrimoz® (adalimumab-adaz) became commercially available in the United States. Hyrimoz® is a citrate-free, high-concentration formulation biosimilar to Humira® (adalimumab). [1]
Hyrimoz® is a TNF blocker that is approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It is available as an autoinjector. [1]
This high-concentration formulation offers a reduction in injection volume compared to the 50 mg/mL formulation and may decrease the number of injections required for some patients. [1]
